Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PHGE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — NYSE delisting notice for equity deficiency; must regain compliance by September 2027 or face delisting.
- Departure of CEO (new) — Entire management team and board replaced in Q1 2026 as part of strategic pivot from biotech to defense.
- Departure of CFO (new) — Entire management team and board replaced in Q1 2026 as part of strategic pivot from biotech to defense.
BiomX abandons biotech, pivots to Israeli defense tech amid NYSE delisting risk
Filed May 5, 2026 · Period ending May 5, 2026 · ~1 min read
Key Changes
-
high
Company exited phage therapy entirely: discontinued lead drug BX004, Israeli subsidiary BiomX Ltd. filed insolvency and is now under court-appointed trustee. Parent company lost control of former core operating asset.
Item 8.01 verify on EDGAR → -
high
Now operates three Israeli defense subsidiaries: DFSL (60% owned, laser radar systems), Zorronet (AI surveillance software with Elbit/Rafael contracts), and X Security (first-response tech including aerial firefighting). Committed $3M+ to fund operations.
Item 8.01 verify on EDGAR → -
high
Received NYSE delisting notice for equity deficiency in March 2026. Must regain compliance by September 2027 or face delisting, which would severely impair liquidity and could trigger convertible note defaults.
Item 8.01 verify on EDGAR → -
high
Entire management team and board replaced in Q1 2026. New CEO Michael Oster and CFO David Rokach installed as part of strategic transformation from biotech to defense technology.
Item 8.01 verify on EDGAR → -
high
Heavy customer concentration: five customers expected to each represent 10%+ of 2026 revenue. All operations in Israel amid ongoing multi-front conflict; employees face military call-ups causing workforce reductions up to 40%. No war risk insurance.
Item 8.01 verify on EDGAR →
Summary
BiomX has executed a complete business transformation, abandoning its biotech roots to become an Israeli defense technology holding company. In December 2025, the company discontinued its lead phage therapy drug candidate and its core Israeli subsidiary filed for insolvency, leaving it under court control.
The parent company installed entirely new management and now operates through three defense-focused subsidiaries developing laser radar detection systems, AI surveillance platforms, and first-response technologies including aerial firefighting. This pivot carries substantial execution risk.
The company faces NYSE delisting by September 2027 if it cannot restore equity compliance, which would devastate liquidity and potentially trigger debt defaults. All operations are concentrated in Israel during active multi-front conflict, with no war risk insurance and employees subject to military call-ups that have caused 40% workforce reductions at peer companies. Revenue depends heavily on a handful of Israeli defense contractors. Retail investors should monitor the September 2027 NYSE compliance deadline closely and watch for Q2-Q3 2026 revenue disclosures to assess whether the defense pivot is generating sustainable cash flow. Any loss of major customer relationships with Elbit or Rafael, or escalation of regional conflict affecting operations, would be material negative catalysts.
Section-by-Section Diff
Event · Item 8.01 — Other Events
BiomX disclosed complete business transformation from phage therapy to defense/security tech via acquisitions, Israeli subsidiary insolvency, and new management.
Added in current filing · verify on EDGAR →
On March 25, 2026, we received a notice from the staff of NYSE American indicating that we are not in compliance with certain continued listing standards relating to stockholders’ equity. We have submitted a compliance plan on April 24, 2026 and must regain compliance by September 25, 2027.
The company is not in compliance with NYSE American's stockholders' equity requirements. It submitted a compliance plan in April 2026 and has until September 2027 to regain compliance. If unsuccessful, the stock could be delisted, which would severely impair liquidity, investor access, and the company's ability to raise capital. Delisting could also trigger defaults on convertible notes.
Added in current filing · verify on EDGAR →
A significant portion of the Company’s expected near-term revenues is dependent on a limited number of key customer relationships, particularly Zorronet’s engagements with Elbit Systems and Rafael Advanced Defense Systems ... the Company expects that, for the fiscal year ending December 31, 2026, approximately five customers may individually account for 10% or more of the Company’s consolidated revenues
BiomX's new defense business is highly concentrated: Zorronet has active projects with major Israeli defense contractors Elbit Systems (NIS 615,000 in contracts disclosed) and Rafael Advanced Defense Systems (approximately $800,000 three classified projects). The company expects roughly five customers to each represent 10%+ of 2026 revenue, creating significant customer concentration risk. Loss of any major customer relationship could materially impact financial performance.
Added in current filing · verify on EDGAR →
Since October 7, 2023, Israel has been engaged in an ongoing multi-front military conflict ... The majority of our operations, employees, and subsidiaries are located in Israel ... a significant number of our employees have been called up for military reserve duty, creating recurring personnel shortages ... Israeli companies in our sector experienced workforce reductions of up to 40% and operational suspensions lasting 60 days or more ... We do not carry war risk insurance for our Israeli operations, and losses arising from military conflict would be entirely unrecovered.
All of BiomX's operating subsidiaries and most employees are in Israel, which has been in active multi-front conflict since October 2023. Key personnel are subject to mandatory military reserve duty with unpredictable call-ups that have caused workforce reductions up to 40% at peer companies. The company carries no war risk insurance, meaning any conflict-related damage to facilities, equipment, or personnel would be entirely uninsured. The conflict has also created export restrictions and reputational risks for Israeli defense companies.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify